These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 8000261

  • 1. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H.
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [Abstract] [Full Text] [Related]

  • 2. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A, Boneu B, Bosser C, Cazenave JP, Dirat G, Gazengel G, Grunebaum L, Sultan Y, Verroust F, Wiesel ML.
    Nouv Rev Fr Hematol (1978); 1988 Aug; 30(4):205-7. PubMed ID: 3143099
    [Abstract] [Full Text] [Related]

  • 3. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA.
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [Abstract] [Full Text] [Related]

  • 4. Substitution treatment of hemophilia a and b.
    Duckert F.
    Schweiz Med Wochenschr; 1975 Jun 14; 105(24):783-4. PubMed ID: 1145162
    [Abstract] [Full Text] [Related]

  • 5. Blood safety and the choice of anti-hemophilic factor concentrate.
    Janco RL.
    Pediatr Blood Cancer; 2007 Jan 14; 48(1):117. PubMed ID: 17063470
    [No Abstract] [Full Text] [Related]

  • 6. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E, Mauser-Bunschoten EP.
    Ned Tijdschr Geneeskd; 1997 Dec 27; 141(52):2566-71. PubMed ID: 9555158
    [Abstract] [Full Text] [Related]

  • 7. [Hemophilia and HTLV-III infection].
    Lechler E.
    Z Hautkr; 1986 Dec 01; 61(23):1687-704. PubMed ID: 2949442
    [Abstract] [Full Text] [Related]

  • 8. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V, Parquet A, Tahiri C, Claeyssens S, Potard V, Faradji A, Peynet J, Costagliola D, Suivi Thérapeutique National des Hémophiles Group.
    Br J Haematol; 2002 Feb 01; 116(2):383-9. PubMed ID: 11841442
    [Abstract] [Full Text] [Related]

  • 9. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
    Heimburger N, Karges HE, Weidmann E.
    Dev Biol Stand; 1987 Feb 01; 67():303-10. PubMed ID: 3038638
    [Abstract] [Full Text] [Related]

  • 10. [Clinical evaluation of factors VIII and IX manufactured in Hungary, based on results of the first half year].
    Nemes L, Ceglédi A, Szabó G, Varga M, Sas G.
    Orv Hetil; 1998 Mar 29; 139(13):749-52. PubMed ID: 9578703
    [Abstract] [Full Text] [Related]

  • 11. Advances in the care and treatment of children with hemophilia.
    Manco-Johnson MJ.
    Adv Pediatr; 2010 Mar 29; 57(1):287-94. PubMed ID: 21056743
    [No Abstract] [Full Text] [Related]

  • 12. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P, Gensana M, Fernández J, Massot M, Biescas H, Darling A, Jorquera JI, Vericat F.
    Sangre (Barc); 1996 Apr 29; 41(2):131-6. PubMed ID: 9045353
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Prevention of transfusion-associated virus infections in hemophilic patients needing replacement therapy].
    Meili EO.
    Beitr Infusionsther; 1989 Apr 29; 24():46-55. PubMed ID: 2481548
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of hemophilia].
    Stavem P, Hjort PF.
    Tidsskr Nor Laegeforen; 1970 Jul 01; 90(13):1413-8. PubMed ID: 5453192
    [No Abstract] [Full Text] [Related]

  • 16. Specific therapy in hemophilia.
    Hutaff LW.
    N C Med J; 1973 Mar 01; 34(3):193-6. PubMed ID: 4510809
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of self-therapy in hemophilia. A study of 72 patients with hemophilia A and B.
    Levine PH.
    N Engl J Med; 1974 Dec 26; 291(26):1381-4. PubMed ID: 4427642
    [No Abstract] [Full Text] [Related]

  • 18. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D.
    Cas Lek Cesk; 2006 Dec 26; 145(2):104-11. PubMed ID: 16521398
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C, Menart C, Attali O, Petit PY, Lienhart A, Dechavanne M, Ingerslev J.
    Blood Coagul Fibrinolysis; 1998 Mar 26; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [Abstract] [Full Text] [Related]

  • 20. [Concentrated antihemophilic globulin in the treatment of hemorrhagic syndromes].
    Baklaja F, Cvetković V, Stajić M, Krivokapić L.
    Bilt Hematol Transfuz; 1976 Mar 26; 4(3):61-6. PubMed ID: 1008799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.